NKGEN BIOTECH INC (NKGN)
US65488A1016 - Common Stock
NKGEN BIOTECH INC
NASDAQ:NKGN (5/6/2024, 7:17:30 PM)
After market: 1.34 0 (0%)1.34
-0.09 (-6.29%)
Company Profile
NKGen Biotech Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Santa Ana, California. The company went IPO on 2021-05-21. NKGen Biotech, Inc. is a clinical-stage biotechnology company. The firm is focused on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies to treat neurodegenerative and oncological diseases utilizing its (SuperNK) SNK (super-activated) platform. SNK involves the infusion of one’s own activated NK cells into the body to improve immune system function, eliminate diseased or abnormal cells and prevent recurrence. SNK uses pure NK cells harvested from the patient’s blood, activated and infused back into the patient’s body. SNK has a therapeutic potential within the areas of cancer, autoimmune and neurodegenerative diseases. Autologous NK cell immunotherapy is a treatment that provides immune enhancement using pure NK cells harvested from a patient’s body. The company is also focused on conducting clinical trials with its super-activated NK cell therapy in patients with neurodegenerative disease (SNK01) and cancer (SNK02).
Company Info
NKGEN BIOTECH INC
3001 Daimler St,
Santa Ana CALIFORNIA
P: 19493966830
Employees: 0
Website: https://nkgenbiotech.com/
NKGN News
11 days ago - ChartmillTop movers in Friday's sessionLet's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.
In vitro studies with SNK01 have shown a direct ability to phagocytose and digest amyloid and alpha-synuclein proteins while also secreting...
SANTA ANA, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology...
13 days ago - ChartmillWednesday's pre-market session: top gainers and losersStay updated with the stocks that are on the move in Wednesday's pre-market session.
14 days ago - ChartmillTuesday's pre-market session: top gainers and losersAs we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
NKGen Biotech Inc (NASDAQ:NKGN) shares traded higher on Monday, with a strong session volume of 19.25 million, compared to an average 100-day volume of 2.85 million, according to data from Benzinga Pro. However, there is no news to justify the +20% increase in the stock price. NKGen Biotech will present details about its NK cell therapy for neurodegenerative disease, review its preclinical data for Parkinson’s disease, and highlight clinical safety and efficacy data from the recently completed P
NKGN Twits
Here you can normally see the latest stock twits on NKGN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
